Sensei Biotherapeutics, Inc. (SNSE)

Sensei Biotherapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-184.46	-21.09	-30.16	-34.1	-48.59	-36.79
Depreciation & Amortization	0.12	0.12	0.55	0.57	0.61	0.69
Stock-Based Compensation	13.71	1.27	3.14	4.45	5.81	5.66
Other Adjustments	133.97	0.83	2.29	1.38	2.13	0.08
Changes in Accounts Payable	-0.98	0.23	-0.45	-2.33	2.02	-1.43
Changes in Other Operating Activities	13.57	-1.83	-0.04	-2	-1.01	1.54
Operating Cash Flow	-24.09	-20.45	-24.67	-32.02	-39.03	-30.26
Capital Expenditures	-0.02	-0.02	-0.15	-0.18	-0.32	-2.03
Sale of Property, Plant & Equipment	0.21	0.25	-	0.17	0.02	0.32
Purchases of Investments	-62.7	-25.16	-44.6	-21.15	-46.87	-183.67
Proceeds from Sale of Investments	37.19	44.69	67.18	59.58	97.12	42.26
Payments for Business Acquisitions	6.46	-	-	-	-	-
Investing Cash Flow	-18.86	19.77	22.44	38.41	49.95	-143.12
Issuance of Common Stock	1.04	0.01	0.03	0.05	0.34	140.7
Repurchase of Common Stock	-0	-0	-0.01	-10.46	-	-
Net Common Stock Issued (Repurchased)	1.04	0	0.02	-10.41	0.34	140.7
Issuance of Preferred Stock	200	-	-	-	-	23.49
Net Preferred Stock Issued (Repurchased)	200	-	-	-	-	23.49
Other Financing Activities	-15.72	-0.65	-0.81	-0.76	-0.63	-0.26
Financing Cash Flow	185.4	-0.65	-0.79	-11.17	-0.29	163.94
Net Cash Flow	142.45	-1.33	-3.02	-4.78	10.64	-9.44
Free Cash Flow	-24.11	-20.47	-24.82	-32.2	-39.35	-32.29
Free Cash Flow Per Share	-18.99	-16.24	-19.76	-23.04	-25.63	-23.30
Levered Free Cash Flow	-171.77	-22.57	-30.24	-38.04	-47.29	-38.02
Unlevered Free Cash Flow	-172.96	-23.77	-32.7	-41	-48.89	-38.71

Updated May 15, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q